The incidence of cardiovascular disease is increasing worldwide. Despite many new developments in both medical and surgical specialities, a substantial number of cardiac patients are not suitable candidates for one of the current treatment options. This “no-option” subgroup of patients is a driving influence in the rapidly developing field of angiogenesis. In this review, we discuss the different modalities of treatment being tried for these patients and the patents which have been filed to improve cardiac angiogenesis.
Keywords: VEGF in cardiac angiogenesis, angiogenic drug delivery, FGF in cardiac angiogenesis, protein based therapy for cardiac angiogenesis, gene based therapy for cardiac angiogenesis, cardiac angiogenesis in myocardial ischemia, cardiac angiogenesis in myocardial infarction, Angiogenesis, cardiovascular disease, VEGF, coronary artery, thrombolytic therapy, percutaneous intravascular coronary intervention, coronary artery bypass grafting, nerve stimulation, transcutaneous laser revasularization, neoangiogenesis technology, primitive stem cell, vasculogenesis, intussusception, arteriogenesis, endothelial progenitor cell, antagonistic promoter and inhibitor substances, Vascular endothelial growth factor, heparin, placental growth factor (PIGF), Angiopoietins, Tie receptors, pericytes, smooth muscle, vascular remodeling, vascular regression, Integrins, Semaphorins, collateral vessels, hypoxia-inducible factor (HIF-), bradycardia, diastolic, angina, Streptokinase, Anistreplase, Recombinant tissue type plasminogen activator, Reteplase, Tenecteplase, Lanoteplase, angioplasty, fibrinolyis, retrograde coronary venous delivery, Gene Therapy, Placental growth factor, Stem Cell Transplantation, vascular progenitor cell, endothelial progenitor cells
Rights & PermissionsPrintExport
Published on: 01 March, 2012
Page: [171 - 176]